Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 852-860

  Wheeler, Amanda J ^a,b,c  

^a WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Waitemata District Health Board   (New Zealand)

Author keywords

Audit; Clozapine; Prescribing; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZATROPINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DIAZEPAM; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PROCYCLIDINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SULPIRIDE; TEMAZEPAM; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZOPICLONE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PATHWAY; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMMUNITY MENTAL HEALTH CENTER; COMORBIDITY; CONSTIPATION; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DRUG POTENTIATION; DRUG USE; ENDOCRINE DISEASE; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HEARTBURN; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; HYPERSALIVATION; HYPERTENSION; INTESTINE MOTILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL HOSPITAL; MENTAL PATIENT; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEW ZEALAND; OBESITY; OUTPATIENT CARE; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMMUNITY MENTAL HEALTH SERVICES; CROSS-SECTIONAL STUDIES; FEMALE; FINANCING, GOVERNMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFORMATION DISSEMINATION; MALE; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SIALORRHEA; TREATMENT OUTCOME;

EID: 44649095299     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K662     Document Type: Article

References (58)

1. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000: CD000059.
2. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 1989;99(suppl):S68-72.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
4. Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32: 715-23.
5. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10.
6. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
7. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005;73:139-45.
8. Morris S, Hogan T, McGuire A. The cost-effectiveness of clozapine: a survey of the literature. Clin Drug Invest 1998;15:137-52.
9. Reid WH, Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. J Clin Psychiatry 1998;59:189-94.
10. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington, DC: American Psychiatric Association, 2004.
11. National Institute for Clinical Evidence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Evidence, 2002.
12. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1-30.
13. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-21.
14. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-61.
15. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
16. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345:224-5.
17. Douglas Pharmaceuticals Ltd. Data sheet: Clopine. Wellington, NZ: New Zealand Medicines and Medical Devices Safety Authority, Ministry of Health, October 4, 2007.
18. Novartis New Zealand Ltd. Data sheet: Clozaril. Wellington, NZ: New Zealand Medicines and Medical Devices Safety Authority, Ministry of Health, October 4, 2007.
19. New Zealand Mental Health Metabolic Working Group. A New Zealand Mental Health Metabolic Working Group Initiative. Auckland, NZ: Janssen Cilag Ltd, 2006.
20. Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 2003;182:505-8.
21. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophr Bull 2002;28:31-42.
22. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003;64:30-4.
23. Essock SM. Antipsychotic prescribing practices. Schizophr Bull 2002; 28:1-4.
24. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical correlates of clozapine prescription for schizophrenia in China. Hum 2007; 22:17-25.
25. Mahy P. A bitter pill? North & South 1995:88-95.
26. Mental Health Commission. New Zealand's National Mental Health Strategy; review of progress 1994-1999. Wellington, NZ: Mental Health Commission, 1999.
27. Ministry of Health. Toward clinical excellence; an introduction to clinical audit, peer review and other clinical practice improvement activities. Wellington, NZ: Ministry of Health, 2002. www.moh.govt.nz/moh.nsf/ pagesmh/334?Open (accessed 2007 Oct 4).
28. Walker RA. 2001 Demographic profile for Auckland District Health Board: an analysis of 2001 Census. Auckland, NZ: Regional Decision Support Team, Northern DHB Support Agency (NDSA), 2002.
29. Walker RA. 2001 Demographic profile for counties Manukau District Health Board: an analysis of 2001 Census. Auckland, NZX: Regional Decision Support Team, Northern DHB Support Agency (NDSA), 2002.
30. Walker RA. 2001 Demographic profile for Northland District Health Board: an analysis of 2001 Census. Auckland, NZ: Regional Decision Support Team, Northern DHB Support Agency (NDSA), 2002.
31. Walker RA. 2001 Demographic profile for Waitemata District Health Board: an analysis of 2001 Census. Auckland, NZ: Regional Decision Support Team, Northern DHB Support Agency (NDSA), 2002.
32. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
33. Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 2004;38:240-5.
34. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology 2006;185: 265-73.
35. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56:1-10.
36. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27.
37. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21.
38. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178:s67-s70.
39. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007;64:242-9.
40. Ellis PM, Mclean RM, Harrison-Woolrych M. Clozapine: fatal 'constipation' more common than fatal agranulocytosis. Medsafe Prescriber Update 2007;28:7. www.medsafe.govt.nz/Profs/PUArticles/clozGI.htm (accessed 2007 Oct 4).
41. Conley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv 2005;56:320-3.
42. Keks NA, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999;33:896-901.
43. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994;55:78-81.
44. Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007;58:489-95.
45. Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27:369-73.
46. Kerwin R. When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine. CNS Drugs 2007;21: 267-78.
47. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-9.
48. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88.
49. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
50. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6.
51. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354:472-82.
52. Anil Yaciolu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
53. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92:90-4.
54. National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment of schizophrenia in primary and secondary care. Clinical guideline 1. London: National Institute for Clinical Excellence, 2002.
55. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-8.
56. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005;56:283-91.
57. Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig 1999;17:97-102.
58. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843-72.